Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRTIVITY Phase III study of BI 1291583 in bronchiectasis
jRCT2071250036Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in bronchiectasis comparing BI 1291583 2.5 mg once daily with Placebo once daily (2 arms). Primary endpoint: Annualized rate of pulmonary exacerbations up to Week 76. Started Aug 2025; status: active, not recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2071250036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250036.